AD BBB Modulation and Transport Technologies

Overview

Blood-brain barrier (BBB) modulation and transport technologies represent a critical frontier in Alzheimer's disease therapeutics. The BBB — while essential for protecting the brain from pathogens and toxins — blocks approximately 98% of small molecule drugs and nearly all large molecule therapeutics, severely limiting treatment options for CNS disorders. This category page catalogs companies developing technologies to overcome this fundamental challenge.

The key approaches include:

• Receptor-mediated transcytosis (RMT): Leveraging endogenous transport receptors
• Adsorptive transcytosis: Using cationized molecules to trigger uptake
• Efflux pump inhibition: Blocking P-glycoprotein and other export transporters
• BBB normalization: Repairing barrier function rather than bypassing it
• Nanocarrier delivery: Engineered particles for CNS penetration
• Trojan horse approaches: Using endogenous peptides as delivery vehicles

Key Companies and Technologies

Denali Therapeutics (LRP1/Transferrin Pathway)

Denali Therapeutics has developed a proprietary Transport Vehicle (TV) platform that enables delivery of large therapeutic molecules across the BBB via receptor-mediated transcytosis[@denali_tv]:

| Attribute | Details |
|-----------|---------|
| Focus | LRP1-based brain delivery platform |
| Platform | Transport Vehicle (TV) technology |
| Mechanism | LRP1-mediated transcytosis across BBB |
| Stage | Multiple clinical programs |

Overview

Blood-brain barrier (BBB) modulation and transport technologies represent a critical frontier in Alzheimer's disease therapeutics. The BBB — while essential for protecting the brain from pathogens and toxins — blocks approximately 98% of small molecule drugs and nearly all large molecule therapeutics, severely limiting treatment options for CNS disorders. This category page catalogs companies developing technologies to overcome this fundamental challenge.

The key approaches include:

• Receptor-mediated transcytosis (RMT): Leveraging endogenous transport receptors
• Adsorptive transcytosis: Using cationized molecules to trigger uptake
• Efflux pump inhibition: Blocking P-glycoprotein and other export transporters
• BBB normalization: Repairing barrier function rather than bypassing it
• Nanocarrier delivery: Engineered particles for CNS penetration
• Trojan horse approaches: Using endogenous peptides as delivery vehicles

Key Companies and Technologies

Denali Therapeutics (LRP1/Transferrin Pathway)

Denali Therapeutics has developed a proprietary Transport Vehicle (TV) platform that enables delivery of large therapeutic molecules across the BBB via receptor-mediated transcytosis[@denali_tv]:

| Attribute | Details |
|-----------|---------|
| Focus | LRP1-based brain delivery platform |
| Platform | Transport Vehicle (TV) technology |
| Mechanism | LRP1-mediated transcytosis across BBB |
| Stage | Multiple clinical programs |

Scientific Rationale: The Transport Vehicle platform exploits the LRP1 (Low-Density Lipoprotein Receptor-related Protein 1) pathway, which is naturally expressed on brain endothelial cells and mediates uptake of various ligands. By engineering therapeutics to engage LRP1, Denali achieves 10-30x higher brain exposure compared to conventional delivery methods.

Clinical Applications:

• DNL310 (ENHANZE): Iduronate-2-sulfatase (IDS) enzyme with TV technology for Hunter syndrome — demonstrates CNS delivery of enzyme therapeutics[@denali_tv]
• Multiple CNS programs in development for neurodegenerative diseases

• [Denali Therapeutics](/companies/denali-therapeutics) — Company page
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier) — Mechanism page

Alnylam Pharmaceuticals (TfR siRNA Delivery)

Alnylam is pioneering RNA interference (RNAi) therapeutics with a focus on brain delivery through transferrin receptor (TfR)-targeting[@alnylam_tfr]:

| Attribute | Details |
|-----------|---------|
| Focus | siRNA delivery to brain via TfR |
| Platform | GALNAc-conjugated siRNA with TfR targeting + TRiM™ |
| Indication | CNS diseases including AD |
| Stage | Phase 1 (ALN-APP) |

Innovation: Alnylam's TfR-targeted approach enables siRNA delivery across the BBB. The company's TRiM™ (Targeted RNAi Molecule) platform was developed specifically for tissue-specific delivery including the CNS[@alnylam_tfr].

Key Programs:

• ALN-APP: siRNA targeting amyloid precursor protein (APP) — Phase 1 ongoing
• ALN-PACK: siRNA targeting APOE4 allele — Discovery
• Multiple CNS programs targeting genetically validated targets

• [Alnylam Pharmaceuticals](/companies/alnylam) — Company page
• [RNAi therapeutics](/mechanisms/rna-interference-therapeutics) — Mechanism page

Emerging BBB Transport Technologies

The following companies are developing additional BBB modulation approaches:

Angiex (Anti-Notch1/VEGF for BBB Normalization)

Angiex is developing therapies targeting Notch1 and VEGF signaling to normalize BBB function:

| Attribute | Details |
|-----------|---------|
| Focus | BBB normalization through VEGF/Notch modulation |
| Approach | Restore barrier integrity |
| Stage | Preclinical |

Rationale: VEGF (Vascular Endothelial Growth Factor) plays a critical role in maintaining BBB integrity. Dysregulation of VEGF signaling contributes to barrier breakdown in Alzheimer's disease. Angiex's approach aims to normalize signaling rather than bypass the barrier.

Phranch (BBB Shuttle Proteins)

Phranch is developing engineered BBB shuttle proteins:

| Attribute | Details |
|-----------|---------|
| Focus | Engineered protein scaffolds for BBB crossing |
| Mechanism | Receptor-mediated transcytosis |
| Stage | Discovery |

Excivia (Transport Technology)

Excivia is developing next-generation transport technologies:

| Attribute | Details |
|-----------|---------|
| Focus | Novel BBB-crossing platforms |
| Approach | Multiple mechanisms |
| Stage | Discovery |

Therapeutic Approaches

1. Receptor-Mediated Transcytosis (RMT)

RMT exploits natural transport pathways used by essential molecules[@pardone2018]:

| Target Receptor | Natural Ligand | Therapeutic Application |
|---------------|----------------|------------------------|
| Transferrin receptor (TfR) | Transferrin | Antibodies, siRNAs |
| LDL receptor (LDLR) | Apolipoproteins | Lipidated therapeutics |
| LRP1 | ApoE, clusterin | Large proteins, enzymes |
| Insulin receptor | Insulin | Peptide therapeutics |

Companies Active in RMT: Denali, Alnylam, Roche, Lundbeck, AbbVie

2. Adsorptive Transcytosis

Adsorptive transcytosis uses cationized molecules to bind negatively charged membrane lipids:

| Approach | Description | Companies |
|----------|------------|-----------|
| Cationized proteins | Positively charged protein domains | Research |
| Cell-penetrating peptides | CPPs for intracellular delivery | Research |
| Poly-arginine conjugates | Arginine-rich sequences | Research |

3. Efflux Pump Inhibition

The ABC transporter family (P-glycoprotein, BCRP, MRPs) limits drug penetration into the brain[@abbott2022]:

| Target | Function | Inhibition Strategy |
|--------|----------|--------------------|
| P-glycoprotein (ABCB1) | Major efflux pump | Verapamil, tariquidar |
| BCRP (ABCG2) | Breast cancer resistance protein | Ko143 |
| MRP1-5 (ABCC1-5) | Multidrug resistance | Various inhibitors |

Clinical Challenge: Systemic efflux pump inhibitors have dose-limiting toxicity. Current approaches focus on localized delivery or substrate engineering.

4. BBB Normalization

Rather than bypassing the barrier, BBB normalization aims to restore integrity:

| Target | Approach | Companies |
|--------|----------|---------|
| Tight junction proteins | Claudin-5, occludin stabilization | Angiex, research |
| Pericyte function | PDGF-BB agonists | Research |
| VEGF signaling | Normalization | Angiex |
| Astrocyte endfeet | AQP4 polarization | Research |

5. Nanocarrier Delivery

Nanoparticle delivery systems offer multiple advantages[@joshi2020]:

| Nanocarrier Type | Advantages | Applications |
|-----------------|------------|--------------|
| Liposomes | Flexible surface modification | Protein delivery |
| Polymeric nanoparticles | Controlled release | Small molecules |
| Dendrimers | Multiple functional groups | siRNA delivery |
| Solid lipid nanoparticles | Biocompatible | Peptides |
| Exosomes | Endogenous origin | Multiple |

Companies: NanoCarrier, Medesis, research programs

6. Trojan Horse Approaches

Trojan horse approaches use endogenous peptides as delivery vehicles:

| Trojan Horse | Target | Cargo | Companies |
|-------------|--------|-------|----------|
| Angiopep-2 | LRP1 | Chemotherapeutics | Angiex |
| Apamin | Unknown | Peptides | Research |
| Tat peptide | Cell entry | Various | Research |
| Syn-B polymer | LRP1 | Proteins | Research |

Mechanism Categories

Receptor-Mediated Transcytosis

Trojan Horse Technology

Clinical Trial Landscape

| Company | Technology | Therapeutic | Phase | Indication |
|---------|------------|-------------|-------|------------|
| Denali | TV platform | DNL310 | Phase 2/3 | Hunter syndrome |
| Alnylam | TRiM™ + TfR | ALN-APP | Phase 1 | Alzheimer's disease |
| Roche | Brain Shuttle | RG6182 | Phase 1 | Parkinson's disease |
| Lundbeck | Bispecific | - | Discovery | CNS diseases |
| AbbVie | BRAIN platform | - | Discovery | AD/PD |

Scientific Rationale

Why BBB Delivery Matters for AD

Evidence Supporting BBB Technologies

Cross-Links

• [Alzheimer's Disease Pipeline](/companies/ad-pipeline)
• [AD Neurovascular and Cerebral Vasculature Therapy Companies](/companies/ad-neurovascular-cerebral-vasculature-therapy-companies)
• [Emerging Novel Mechanism AD Companies](/companies/emerging-novel-mechanism-ad-companies-2024-2025)
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
• [Blood-Brain Barrier Dysfunction](/mechanisms/blood-brain-barrier-dysfunction)
• [Neurovascular Unit](/mechanisms/neurovascular-unit)
• [Nanoparticle Brain Delivery](/technologies/nanoparticle-brain-delivery)
• [Brain Shuttle Technologies](/technologies/brain-shuttle-technologies)
• [Denali Therapeutics](/companies/denali-therapeutics)
• [Alnylam Pharmaceuticals](/companies/alnylam)

References